Hisoar Pharmaceutical Overview
- Year Founded
-
1966
- Status
-
Public
- Employees
-
2,612
- Stock Symbol
-
002099
- Investments
-
2
- Share Price
-
$0.83
- (As of Friday Closing)
Hisoar Pharmaceutical General Information
Description
Zhejiang Hisoar Pharmaceutical Co Ltd is a China-based company engages in the production of specialty raw materials, preparations and fine chemicals, dyes and dye intermediates. Its products include Clindamycin hydrochloride, Clindamycin phosphate, Florfenicol, Atova, Thiamphenicol, and Riglinay.
Contact Information
Website
www.hisoar.comCorporate Office
- 100 Waisha Road, Jiaojiang District
- Taizhou, Zhejiang 318000
- China
Corporate Office
- 100 Waisha Road, Jiaojiang District
- Taizhou, Zhejiang 318000
- China
Hisoar Pharmaceutical Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.83 | $0.88 | $0.55 - $1.41 | $1.42B | 1.62B | 8.59M | -$0.03 |
Hisoar Pharmaceutical Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,101,110 | 1,559,358 | 1,556,764 | 1,880,599 |
| Revenue | 279,902 | 306,986 | 401,534 | 384,822 |
| EBITDA | (15,218) | (18,656) | 65,394 | 62,899 |
| Net Income | (55,740) | (59,373) | 13,069 | 14,748 |
| Total Assets | 1,050,048 | 1,060,871 | 1,216,515 | 1,258,208 |
| Total Debt | 170,377 | 148,621 | 145,008 | 92,912 |
Hisoar Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hisoar Pharmaceutical Patents
Hisoar Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2647624-B1 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | ||
| EP-2647624-A1 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | ||
| EP-2647624-A4 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | ||
| US-20130281695-A1 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | ||
| US-9187419-B2 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | C07C323/25 |
Hisoar Pharmaceutical Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| Yong Zhu | Chief Financial Officer | |
| Yang Sun | Chairman & General Manager |
Hisoar Pharmaceutical Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Yang Sun | Hisoar Pharmaceutical | Chairman & General Manager |
Hisoar Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hisoar Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hisoar Pharmaceutical Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visum Pharmaceutical | 29-Jun-2022 | Drug Discovery | |||
| Taizhou Qianjin Chemicals | 01-Oct-2014 | Merger/Acquisition | Other Commercial Services |
Hisoar Pharmaceutical ESG
Risk Overview
Risk Rating
Updated March, 02, 2023
31.99 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Pharmaceuticals
Subindustry
of 446
Rank
Percentile
Hisoar Pharmaceutical FAQs
-
When was Hisoar Pharmaceutical founded?
Hisoar Pharmaceutical was founded in 1966.
-
Where is Hisoar Pharmaceutical headquartered?
Hisoar Pharmaceutical is headquartered in Taizhou, China.
-
What is the size of Hisoar Pharmaceutical?
Hisoar Pharmaceutical has 2,612 total employees.
-
What industry is Hisoar Pharmaceutical in?
Hisoar Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Hisoar Pharmaceutical a private or public company?
Hisoar Pharmaceutical is a Public company.
-
What is Hisoar Pharmaceutical’s stock symbol?
The ticker symbol for Hisoar Pharmaceutical is 002099.
-
What is the current stock price of Hisoar Pharmaceutical?
As of 11-Oct-2024 the stock price of Hisoar Pharmaceutical is $0.83.
-
What is the current market cap of Hisoar Pharmaceutical?
The current market capitalization of Hisoar Pharmaceutical is $1.42B.
-
What is Hisoar Pharmaceutical’s current revenue?
The trailing twelve month revenue for Hisoar Pharmaceutical is $280M.
-
What is Hisoar Pharmaceutical’s annual earnings per share (EPS)?
Hisoar Pharmaceutical’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
